



SolAeroMed Inc.
Unit 2, Research Transition Facility
3535 Research Road N.W.
Calgary, Alberta, Canada T2L 2K8

Email: info@solaeromed.com

SolAeroMed Shareholder Newsletter March 7, 2016 Re: \$1 Million Equity Raise

Hello SolAeroMed shareholders,

Further to our newsletter of February 22, 2016 I write to share news that the SolAeroMed Board has approved initiation of an equity raise of \$1 Million cash through the sale of shares, with each share valued at \$7.50.

Current investors would have an investment threshold of \$10,000. On March 21, 2016 we will extend this offer to outside investors – same share price, but at a higher \$25,000 investment threshold for outside investors. SolAeroMed Inc currently has some 2.2 million shares outstanding. Interested shareholders are advised to review our presentation in the [investor](#) section of www.solaeromed.com.

Further, we are pleased to share news that SolAeroMed has been awarded \$200,000 in new Industrial Research Assistance Program ([IRAP](#)) grant funding to start April 1st. This grant augments a \$150,000 National Research Council (NRC) grant awarded to us in December. All great news, but we must leverage both grants from our operational budget. The additional \$1 Million investment we now seek will be used to: support ongoing operations including leverage for new research grants as well as funding further strategic development of our drug and device technologies. Moreover, the investment will provide a more secure runway for us to negotiate a deal around our S1226 asthma drug,

Please contact Gareth or myself with any questions and to request paperwork around this investment opportunity.

Sincerely

John Dennis
CEO, SolAeroMed
jdennis@solaeromed.com

Gareth Lewis
CFO, SolAeroMed
gareth.lewis@solaeromed.com